Abstract
e18540Background: PON demonstrated efficacy in pts with highly-resistant CP-CML in the pivotal PACE trial. Introduced to the US market in Dec’12, PON was reintroduced in Jan’14 after an 11-wk withd...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
